10:48:17 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-20 Kvartalsrapport 2024-Q2
2024-04-11 Årsstämma 2024
2024-03-20 Bokslutskommuniké 2023
2023-12-06 Split ORPHA 1000:1
2023-11-02 Extra Bolagsstämma 2023
2023-09-12 Kvartalsrapport 2023-Q2
2023-05-22 Ordinarie utdelning ORPHA 0.00 DKK
2023-05-17 Årsstämma 2023
2023-04-25 Bokslutskommuniké 2022
2022-09-26 Kvartalsrapport 2022-Q2
2022-06-29 Årsstämma 2022
2022-06-28 Ordinarie utdelning ORPHA 0.00 DKK
2022-06-07 Bokslutskommuniké 2021
2022-02-15 Extra Bolagsstämma 2022
2021-08-31 Kvartalsrapport 2021-Q2
2021-03-26 Ordinarie utdelning ORPHA 0.00 DKK
2021-03-25 Årsstämma 2021
2021-03-02 Bokslutskommuniké 2020
2020-09-21 Extra Bolagsstämma 2020
2020-08-28 Kvartalsrapport 2020-Q2
2020-03-27 Ordinarie utdelning ORPHA 0.00 DKK
2020-03-26 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2020-01-25 Extra Bolagsstämma 2019
2019-08-28 Kvartalsrapport 2019-Q2
2019-03-28 Ordinarie utdelning ORPHA 0.00 DKK
2019-03-27 Årsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-08-28 Kvartalsrapport 2018-Q2
2018-04-13 Ordinarie utdelning ORPHA 0.00 DKK
2018-04-12 Årsstämma 2018
2018-03-15 Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaSmall Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Orphazyme är verksamt inom biokemi. Bolaget är specialiserat mot forskning och utveckling av ovanliga sjukdomar där det finns en brist i funktionen hos värmekokproteiner. Tekniken baseras på arimoklomol, som stimulerar produktionen av värmekokproteiner i celler som upplever en ökad grad av stress och toxicitet. Sjukdomar som ämnar behandlas med bolagets produkter innefattar Gauchers sjukdom och amyotrofisk lateral skleros (ALS). Bolaget har sitt huvudkontor i Köpenhamn.
2023-10-11 10:53:38

As described in Company Announcements 12/2023, the strategy for Orphazyme is to optimize the cost structure of the company, while the search for a new activity is ongoing.

To reduce the running costs, the company has evaluated the current shareholder structure, which is the biggest cost for Orphazyme of being publicly listed due to the costs paid to banks for the depots that hold the Orphazyme shares. This cost is around DKK 600.000 annually.

Today Orphazyme has around 12.000 shareholders, where 82% has less than 1.000 shares (a value less than DKK 1.000), which means that the annual cost of the depots in many cases exceeds the value of the shares in the depot. Through a consolidation of shares at a ratio 1.000:1, the company can reduce the number of depots to approximately 2.500 shareholders, and thereby realize a cost reduction around DKK 400.000 DKK annually (Estimate is based on current shareholder structure) at a one-off cost of around DKK 475.000. The final cost reduction depends on how many depots ultimately are eliminated in connection with the share consolidation.

A Consolidation of Shares means that 1.000 shares are exchanged to 1 (one) new share in Orphazyme. The company will redeem all shares that are not divisible by 1.000 at a predetermined share price. Shareholders who hold below 1.000 shares at the day of the consolidation, will therefore be fully redeemed and no longer be shareholders in Orphazyme. Shareholders who hold more than 1.000 shares will get 1 share for every 1.000 shares, and get any excess shares redeemed in cash at the predetermined share price.

The share price for the exchange of shares is based on the weighted average closing price in the 5 trading days from 4-10 October 2023 leading up to the notice convening the extraordinary General Meeting. Based on the Weighted closing trading price, the shareprice for redemption is set at DKK 0,94 per share above consolidation rate and redemption price is for shares of nominally DKK 1,00.

Examples:
a) A shareholder who on the day of consolidation holds 2.500 shares, will receive 2 new Orphazyme shares as well as a cash payment of DKK 470,00 (500 shares multiplied by DKK 0,94).

b) A shareholder who on the day of consolidation holds 200 shares, will receive a cash payment of DKK 188,00 (200 shares multiplied by DKK 0,94) and no longer be a shareholder in Orphazyme.

If the proposal is adopted at the Extraordinary General Meeting, the consolidation will be executed after the expiry of a 4-week period after the General Meeting (precise dates will be communicated at that time). During the 4-week period up to the consolidation date, shareholders can trade shares if they wish to adapt their shareholdings in connection with the consolidation.

Based on current share structure, Orphazyme expects to redeem shares at a total value between DKK 2-3 million. The redeemed shares are expected to be kept until further decision will be taken at the coming ordinary General Meeting.

Further information about the proposal from the board is described in the Notice Convening the Extraordinary General Meeting, which will be announced separately following this announcement.

Herlev, October 11th, 2023

The Board of Directors 

For additional information, please contact

Michael Hove, Chairman of the board +45 28 12 66 09